По вашему запросу найдено документов: 27
Страница 1 из 3
ПРИРОДА МОНОКЛОНАЛЬНОГО АНТИТЕЛА ЭКУЛИЗУМАБ И ЕГО ПОТЕНЦИАЛ В ОТНОШЕНИИ КОРОНАВИРУСНОЙ ИНФЕКЦИИ COVID-19THE NATURE OF ECULIZUMAB MONOCLONAL ANTIBODY AND ITS POTENTIAL AGAINST CORONAVIRUS INFECTION COVID
Comparative characteristics of obstetric and "population-wide" atypical hemolytic-uremic syndrome in adults; [Сравнительная характеристика акушерского и «общепопуляционного» атипичного гемолитико-уремического синдрома у взрослых] received fresh frozen plasma and 46 pts (60.5%) – complement-blocking drug Eculizumab (Ecu+). In the non
Eculizumab for pregnancy-related atypical hemolytic uremic syndromeEculizumab for pregnancy-related atypical hemolytic uremic syndrome
Late pregnancy complications as a triggers of obstetric atypical hemolytic uremic syndrome treatment with the complement-blocking drug Eculizumab. Almost a half of them (19 out of 40, 47.5%) received
Pregnancy-associated atypical hemolytic-uremic syndrome: Is pregnancy to blame or its complications?). 40 (58%) of 69 patients received a complement-blocking therapy with Eculizumab. In patients receiving
ЭКУЛИЗУМАБ В ТЕРАПИИ ПАТОЛОГИИ СИСТЕМЫ КОМПЛЕМЕНТА ПРИ ПАРОКСИЗМАЛЬНОЙ НОЧНОЙ ГЕМОГЛОБИНУРИИECULIZUMAB IN THE TREATMENT OF COMPLEMENT SYSTEM DISORDERS INCLUDING PAROXYSMAL NOCTURNAL
ЭКУЛИЗУМАБ В ТЕРАПИИ ПАТОЛОГИИ СИСТЕМЫ КОМПЛЕМЕНТА ПРИ ПАРОКСИЗМАЛЬНОЙ НОЧНОЙ ГЕМОГЛОБИНУРИИECULIZUMAB IN THE TREATMENT OF COMPLEMENT SYSTEM DISORDERS INCLUDING PAROXYSMAL NOCTURNAL
Экулизумаб в лечении атипичного гемолитико- уремического синдрома, связанного с беременностью: ретроспективное исследование у 85 пациентокAim. To evaluate the efficacy of prompt and delayed complement inhibition therapy with eculizumab
Obstetric atypical hemolytic uremic syndrome and sepsis: is there a relationship? received eculizumab at a dose of 900 mg once a week for 4 weeks, on the 5th week — 1200 mg once a week
Страница 1 из 3
Фасеты
Партнеры
Индексация
